🔗 Share this article

As the US proceeds with sweeping adjustments to its immunization schedules, one figure has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by expressing skepticism about COVID-19 vaccines in the global health crisis and has focused upon alleged fatalities after COVID-19 vaccination in her brief tenure at the Food and Drug Administration.

Scheduled Shifts to Pediatric Immunization Program

Public health authorities were set to unveil radical revisions to the pediatric vaccination calendar in December, bringing the US with the Danish vaccine program, according to reports – a major change that would put the US out of alignment with many the international standard with little proof for benefit. The planned update has been pushed back until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is set to speak at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the office this year.

A Shift at the FDA

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a greater focus upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending some childhood vaccine recommendations in the US to become more in line with the Danish model, a nation with comprehensive healthcare and a population approximately the population of Wisconsin’s.

In her initial public appearances, she has continued to focus on vaccination policy – usually the domain of Prasad, director of the FDA’s CBER – as opposed to medication approval.

Concerns Over Expertise

Dr. Høeg has no obvious background in drug development, regulation or leadership, which has been customary for previous directors of the biologics center. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for running the drug-regulation department, remarked Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in managing a major agency. She is not an expert in drug approvals.”

Former heads of the center would “grasp regulatory frameworks and the underlying principles of drug development”, said Dr. Janet Woodcock. “Clearly, she has not acquired the kind of background that former directors who headed the center have had.”

The drug center has an vast range of responsibilities at the agency, the former commissioner pointed out.

“Many people just zeroes in on the innovative therapies, but the generic drug division clears numerous generic drugs. There’s a biosimilars program, OTC medication office and so forth, and all of those have to be supervised,” Woodcock explained. “The area you overlook, that is the part that I always told people is going to come back to haunt you.”

Additionally, a major leadership aspect to the position, which oversees in excess of 5,000 personnel. “It’s a enormous administrative position, if you do it right,” the former official said.

Agency Reaction and Disputed Initiatives

When asked about questions about Dr. Høeg's credentials and whether this selection represents increased cooperation among agency officials on immunizations, a press secretary said that the “inquiries are based on incorrect assumptions”.

“This background aligns with the functions of her role,” the official explained, noting the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a contentious one-day drug-approval program that apparently worried her preceding directors. “How are these drugs being chosen for this expedited pathway? Who takes the calls?” Howard asked. “There’s a lot of secrecy happening at the FDA right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards laxer oversight of all drugs, with the exception of immunizations.”

Documented Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a clearer, if troubling, history, some experts said. She released a study using unverified volunteer-provided data to determine the rate of myocarditis after Covid immunization. She advised the Florida surgeon general Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccines are pose a greater threat than they are.

Part of her “desired changes” for the current administration encompassed revising regulations for recently developed shots and discontinuing “optional” immunizations, she stated following the vote on a audio program. At the FDA, Høeg has reportedly suggested preventing young men from getting COVID-19 vaccinations.

“She’s an complete ideologue who starts off with her beliefs and tailors the evidence to accommodate the evidence in a highly misleading, fraudulent fashion,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of fellow contrarians, {like|